Compare Eli Lilly And Co (LLY) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Synchrony Financial — how do they compare? Eli Lilly And Co trades at $1,177 (market cap $1.04T), while Synchrony Financial trades at $72.86 (market cap $23.99B). The key difference: Eli Lilly And Co is far larger — about 43.4× Synchrony Financial's market cap, and Synchrony Financial pays the higher dividend (1.84%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Synchrony Financial for 29 Days on average.
| LLY | SYF | |
|---|---|---|
Market Cap | $1.04T | $23.99B |
Volume | 3,064,878 | 3,813,027 |
Sector | Health | Financials |
52-Week High | $1.28K | $88.47 |
52-Week Low | $799.57 | $63.78 |
Typical Hold Time | 93 Days | 29 Days |
Enterprise Value | $1.09T | $24.23B |
Dividend Yield | 0.59% | 1.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Synchrony Financial (SYF) trades at $72.87, up 1.31% with bullish technical signals despite mixed momentum indicators. The stock shows strong fundamentals with a low P/E of 7.56, robust ROE of 22.23%, and consistent earnings beats. Recent partnerships with OpenAI and Vetspire highlight strategic growth initiatives in AI-driven commerce and veterinary financing.
SYF presents compelling value with attractive valuation metrics and strong profitability, though investors face risks from consumer credit quality and competitive pressures. Analyst consensus targets $87.58 (20% upside) with 61% buy ratings, supporting a positive outlook if the company maintains its earnings trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
